The HTR4 antibody targets the 5-hydroxytryptamine receptor 4 (HTR4), a G protein-coupled receptor (GPCR) that binds serotonin, a key neurotransmitter involved in regulating mood, cognition, and gastrointestinal motility. HTR4 is primarily expressed in the central nervous system (e.g., hippocampus, cortex) and peripheral tissues, including the gastrointestinal tract, where it modulates neurotransmitter release and smooth muscle contraction. Unlike other serotonin receptors, HTR4 is coupled to Gs proteins, activating adenylyl cyclase to increase intracellular cAMP levels. This signaling pathway influences neuronal excitability, synaptic plasticity, and gut peristalsis.
HTR4 antibodies are essential tools for studying receptor localization, expression patterns, and functional roles in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate HTR4's involvement in disorders such as depression, anxiety, irritable bowel syndrome (IBS), and Alzheimer's disease. Research has highlighted HTR4's potential as a therapeutic target, with agonists explored for treating IBS and cognitive deficits, while antagonists may aid in managing anxiety. However, challenges remain in understanding receptor subtype-specific effects and minimizing off-target interactions.
Commercial HTR4 antibodies are typically validated for specificity using knockout controls or siRNA-based silencing. Researchers must optimize protocols to address cross-reactivity with other GPCRs or isoforms. Ongoing studies aim to clarify HTR4's role in neuroprotection and gut-brain axis communication, underscoring its relevance in both neuroscience and gastroenterology.